1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. https://doi.org/10.1371/journal.pmed.0030442
2. Agustí A, Faner R. COPD beyond smoking: new paradigm, novel opportunities. Lancet Respir Med. 2018;6(5):324-326. https://doi.org/10.1016/S2213-2600(18)30060-2
3. Bhatt SP, Soler X, Wang X, et al. Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016;194(2):178-184. https://doi.org/10.1164/rccm.201511-2219OC
4. Williams M, Todd I, Fairclough LC. The role of CD8+ T lymphocytes in chronic obstructive pulmonary disease: a systematic review. Inflamm Res. 2021;70:11-18. https://doi.org/10.1007/s00011-020-01408-z
5. Barceló B, Pons J, Ferrer JM, Sauleda J, Fuster A, Agusti AGN. Phenotypic characterization of T-lymphocytes in COPD: abnormal CD4+ CD25+ regulatory T-lymphocyte response to tobacco smoking. Eur Respir J. 2008;31(3):555-562. https://doi.org/10.1183/09031936.00010407
6. Kim WD, Sin DD. Granzyme B may act as an effector molecule to control the inflammatory process in COPD. COPD. 2024;21(1):2299104. https://doi.org/10.1080/15412555.2023.2299104
7. Isajevs S, Taivans I, Strazda G, et al. Decreased FOXP3 expression in small airways of smokers with COPD. Eur Respir J. 2008;33(1):61-67. https://doi.org/10.1183/09031936.00145307
8. Chu S, Zhong X, Zhang J, Lao Q, He Z, Bai J. The expression of Foxp3 and ROR gamma t in lung tissues from normal smokers and chronic obstructive pulmonary disease patients. Int Immunopharmacol. 2011;11(11):1780-1788. https://doi.org/10.1016/j.intimp.2011.06.010
9. Hou J, Sun Y, Hao Y, et al. Imbalance between subpopulations of regulatory T cells in COPD. Thorax. 2013;68(12):1131-1139. https://doi.org/10.1136/thoraxjnl-2012-201956
10. Ström JE, Pourazar J, Linder R, et al. Airway regulatory T cells are decreased in COPD with a rapid decline in lung function. Respir Res. 2020;21:330. https://doi.org/10.1186/s12931-020-01593-9
11. Šileikiene V, Jurgauskien L. Role of regulatory T cells in pulmonary ageing and COPD development. Int J Mol Sci. 2025;26(8):3721. https://doi.org/10.3390/ijms26083721
12. Kim WD, Chi HS, Choe KH, et al. A possible role for CD8+ and non-CD8+ cell granzyme B in early small airway wall remodeling in centrilobular emphysema. Respirology. 2013;18(4):688-696. https://doi.org/10.1111/resp.12069
13. Kim WD, Chi HS, Choe KH, Kim WS, Hogg JC, Sin DD. The role of granzyme B containing cells in the progression of chronic obstructive pulmonary disease. Tuberc Respir Dis (Seoul). 2020;83(Supple 1):S25-S33. https://doi.org/10.4046/trd.2020.0089
14. Wang L, Liang Y, Zhao C, et al. Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential. Signal Transduct Target Ther. 2025;10:345. https://doi.org/10.1038/s41392-025-02326-4
15. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol. 2005;174(4):1783-1786. https://doi.org/10.4049/jimmunol.174.4.1783
16. Wang W, Zou R, Qiu Y, et al. Interaction networks converging on immunosuppressive roles of granzyme B: special niches within the tumor microenvironment. Front Immunol. 2021;12:670324. https://doi.org/10.3389/fimmu.2021.670324
17. Drokov MY, Davydova JO, Kuzmina LA, et al. Level of Granzyme B-positive T-regulatory cells is a strong predictor biomarker of acute graft-versus-host disease after day +30 after allo-HSCT. Leuk Res. 2017;54:25-29. https://doi.org/10.1016/j.leukres.2017.01.014
18. Salti SM, Hammelev EM, Grewal JL, et al. Granzyme B regulates antiviral CD8+ T cell responses. J Immunol. 2011;187(12):6301-6309. https://doi.org/10.4049/jimmunol.1100891
19. Loebbermann J, Thornton H, Durant L, et al. Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. Mucosal Immunol. 2012;5(2):161-172. https://doi.org/10.1038/mi.2011.62
20. Bem RA, Bos AP, Bots M, et al. Activation of the granzyme pathway in children with severe respiratory syncytial virus infection. Pediatr Res. 2008;63:650-655. https://doi.org/10.1203/PDR.0b013e31816fdc32
21. Nowacki TM, Kuerten S, Zhang W, et al. Granzyme B production distinguishes recently activated CD8(+) memory cells from resting memory cells. Cell Immunol. 2007;247(1):36-48. https://doi.org/10.1016/j.cellimm.2007.07.004
22. Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486-499. https://doi.org/10.1038/nri3862
23. Iga N, Otsuka A, Yamamoto Y, et al. Accumulation of exhausted CD8+ T cells in extramammary Paget's disease. PLoS One. 2019;14(1):e0211135. https://doi.org/10.1371/journal.pone.0211135
24. Zhang J, He T, Xue L, Guo H. Senescent T cells: a potential biomarker and target for cancer therapy. EBioMedicine. 2021;68:103409. https://doi.org/10.1016/j.ebiom.2021.103409
25. Henson SM, Macaulay R, Riddell NE, Nunn CJ, Akbar AN. Blockade of PD-1 or p38 MAP kinase signaling enhances senescent human CD8(+) T-cell proliferation by distinct pathways. Eur J Immunol. 2015;45(5):1441-1451. https://doi.org/10.1002/eji.201445312
26. Wang J, Ioan-Facsinay A, van der Voort EIH, Huizinga TWJ, Toes REM. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol. 2007;37(1):129-138. https://doi.org/10.1002/eji.200636435
27. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30(6):899-911. https://doi.org/10.1016/j.immuni.2009.03.019
28. Santosh Nirmala S, Kayani K, Gliwiński M, et al. Beyond FOXP3: a 20-year journey unravelling human regulatory T-cell heterogeneity. Front Immunol. 2024;14:1321228. https://doi.org/10.3389/fimmu.2023.1321228
29. Hameed A, Truong LD, Price V, Kruhenbuhl O, Tschopp J. Immunohistochemical localization of granzyme B antigen in cytotoxic cells in human tissues. Am J Pathol. 1991;138(5):1069-1075. https://pmc.ncbi.nlm.nih.gov/articles/PMC1886029/
30. Velotti F, Barchetta I, Cimini FA, Cavallo MG. Granzyme B in inflammatory diseases: apoptosis, inflammation, extracellular matrix remodeling, epithelial-to-mesenchymal transition and fibrosis. Front Immunol. 2020;11:587581. https://doi.org/10.3389/fimmu.2020.587581
31. Qin K, Xu B, Pang M, Wang H, Yu B. The functions of CD4 T-helper lymphocytes in chronic obstructive pulmonary disease. Acta Biochim Biophys Sin (Shanghai). 2022;54(2):173-178. https://doi.org/10.3724/abbs.2021009
32. Rao Y, Le Y, Xiong J, Pei Y, Sun Y. NK Cells in the pathogenesis of chronic obstructive pulmonary disease. Front Immunol. 2021;12:666045. https://doi.org/10.3389/fimmu.2021.666045
33. Finicelli M, Digilio FA, Galderisi U, Peluso G. The emerging role of macrophages in chronic obstructive pulmonary disease: the potential impact of oxidative stress and extracellular vesicle on macrophage polarization and function. Antioxidants (Basel). 2022;11(3):464. https://doi.org/10.3390/antiox11030464
34. Ballarin A, Bazzan E, Zenteno RH, et al. Mast cell infiltration discriminates between histopathological phenotypes of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(3):233-239. https://doi.org/10.1164/rccm.201112-2142OC
35. Jogdand P, Mori M, Bergqvist A, Walls A, Sanden C, Erjefalt J. Mapping of eosinophil and basophils in COPD lung tissues. Eur Respir J. 2015;46(suppl 59):PA384. https://doi.org/10.1183/13993003.congress-2015.PA384
36. Bosken CH, Hards J, Gatter K, Hogg JC. Characterization of the inflammatory reaction in the peripheral airways of cigarette smokers using immunocytochemistry. Am Rev Respir Dis. 1992;145(4 Pt 1):911-917. https://doi.org/10.1164/ajrccm/145.4_Pt_1.911
37. Robertson SJ, Messer RJ, Carmody AB, Hasenkrug KJ. In vitro suppression of CD8+ T cell function by Friend virus-induced regulatory T cells. J Immunol. 2006;176(6):3342-3349. https://doi.org/10.4049/jimmunol.176.6.3342
38. Bae AN, Lee H, Yang H, et al. Enhancing regulatory T cell function by mevalonate pathway inhibition prevents liver fibrosis. Biochem Biophys Res Commun. 2025;742:151094. https://doi.org/10.1016/j.bbrc.2024.151094
39. Simon TG, King LY, Zheng H, Chung RT. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol. 2015;62(1):18-23. https://doi.org/10.1016/j.jhep.2014.08.013
40. Blanquiceth Y, Rodríguez-Perea AL, Tabares Guevara JH, et al. Increase of frequency and modulation of phenotype of regulatory T cells by atorvastatin is associated with decreased lung inflammatory cell infiltration in a murine model of acute allergic asthma. Front Immunol. 2016;7:620. https://doi.org/10.3389/fimmu.2016.00620
41. Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr Pharm Des. 2012;18(11):1519-1530. https://doi.org/10.2174/138161212799504803
42. Shahbaza SK, Sadeghia M, Koushkia K, Penson PE, Sahebkar A. Regulatory T cells: possible mediators for the anti-inflammatory action of statins. Pharmacol Res. 2019:149:104469. https://doi.org/10.1016/j.phrs.2019.104469
43. Greca E, Kacimi O, Poudel S, et al. Immunomodulatory effect of different statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials. Eur Heart J Cardiovasc Pharmacother. 2023;9(2):122-128. https://doi.org/10.1093/ehjcvp/pvac047
44. Forero-Peña DA, Gutierrez FRS. Statins as modulators of regulatory T-cell biology. Mediators Inflamm. 2013;2013(1):167086. https://doi.org/10.1155/2013/167086
45. Mira E, León B, Barber DF, et al. Statins induce regulatory T cell recruitment via a CCL1 dependent pathway. J Immunol. 2008;181(5):3524-3534. https://doi.org/10.4049/jimmunol.181.5.3524
46. Carlson A, Smith E, Reid D. The stats are in: an update on statin use in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10(1):2277-2284. https://doi.org/10.2147/COPD.S78875
47. Ingebrigtsen TS, Marott J/l, Nordestgaard BG, Lange P, Hallas J, Vestbo J. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax. 2015;70(1):33-40. https://doi.org/10.1136/thoraxjnl-2014-205795
48. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117-125. https://doi.org/10.1111/j.1472-8206.2004.00299.x
49. Mausner-Fainberg K, Luboshits G, Mor A, et al. The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis. 2008;197(2):829-839. https://doi.org/10.1016/j.atherosclerosis.2007.07.031
50. Overton ET, Sterrett S, Westfall AO, et al. Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1 infected patients. AIDS. 2014;28(17):2627-2631. https://doi.org/10.1097/QAD.0000000000000475
51. Yuan W, Ren X, Zhu J, et al. Single-intraosseous simvastatin injection suppresses cancers via activating CD8+ T cells. Biomed Pharmacother. 2022:155:113665. https://doi.org/10.1016/j.biopha.2022.113665
52. Goldstein MR, Mascitelli L, Pezzetta F. The double-edged sword of statin immunomodulation. Int J Cardiol. 2009;135(1):128-130. https://doi.org/10.1016/j.ijcard.2008.01.023
53. Sule NO, Suissa S. Statins and mortality in COPD: a methodological review of observational studies. COPD. 2023;20(1):284-291. https://doi.org/10.1080/15412555.2023.2242489
54. Lee JH, Lee DS, Kim EK, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med. 2005;172(8):987-993. https://doi.org/10.1164/rccm.200501-041OC
55. Ou XM, Wen FQ, Uhal BD, et al. Simvastatin attenuates experimental small airway remodelling in rats. Respirology. 2009;14(5):734-745. https://doi.org/10.1111/j.1440-1843.2009.01549.x
56. Wright JL, Zhou S, Preobrazhenska O, et al. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med. 2011;183(1):50-58. https://doi.org/10.1164/rccm.201003-0399OC
57. Churg A, Sin DD, Wright JL. Everything prevents emphysema: are animal models of cigarette smoke-induced chronic obstructive pulmonary disease any use? Am J Respir Cell Mol Biol. 2011;45(6):1111-1115. https://doi.org/10.1165/rcmb.2011-0087PS
58. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370(23):2201-2210. https://doi.org/10.1056/NEJMoa1403086
59. Hogg JC, Paré PD, Hackett TL. The contribution of small airway obstruction to the pathogenesis of chronic obstructive pulmonary disease. Physiol Rev. 2017;97(2):529-552 https://doi.org/10.1152/physrev.00025.2015
60. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645-2653. https://doi.org/10.1056/NEJMoa032158
61. Higham A, Quinn AM, Cançado JED, Singh D. The pathology of small airways disease in COPD: historical aspects and future directions. Respir Res. 2019;20:49. https://doi.org/10.1186/s12931-019-1017-y
62. Schaafsma D, Dueck G, Ghavami S, et al. The mevalonate cascade as a target to suppress extracellular matrix synthesis by human airway smooth muscle. Am J Respir Cell Mol Biol. 2011;44(3):394-403. https://doi.org/10.1165/rcmb.2010-0052OC
63. Bercz PA, Kim V, Marchetti N, et al. Statin use in COPDGene subjects is associated with larger airways and fewer exacerbations. Am J Respir Crit Care Med. 2011;183(Supplement_1):A3111. https://academic.oup.com/ajrccm/article/183/Supplement_1/A3111/8617616
64. Mroz RM, Tycinska L, Minarowski L, er al. Pleiotropic effects of add-on atorvastatin therapy during the treatment of COPD patients. Am J Respir Crit Care Med. 2011;183(Supplement_1):A3106. https://academic.oup.com/ajrccm/article/183/Supplement_1/A3106/8618395
65. Young RP, Hopkins RJ. Statins and small airways disease in COPD. Am J Respir Cell Mol Biol. 2013;49(3):501. https://doi.org/10.1165/rcmb.2011-0422LE
66. Soriano JB, Polverino F, Cosio BG. What is early COPD and why is it important? Eur Respir J. 2018;52(6):1801448. https://doi.org/10.1183/13993003.01448-2018
67. Matyori A, Brown CP, Ali A, Sherbeny F. Statins utilization trends and expenditures in the U.S. before and after the implementation of the 2013 ACC/AHA guidelines. Saudi Pharm J. 2023;31(6):795-800. https://doi.org/10.1016/j.jsps.2023.04.002
68. Sorathia N, Al-Rubaye H, Zal B. The effect of statins on the functionality of CD4+CD25+FOXP3+ regulatory T-cells in acute coronary syndrome: a systematic review and meta-analysis of randomised controlled trials in Asian populations. Eur Cardiol. 2019;14(2):123-129. https://doi.org/10.15420/ecr.2019.9.2
69. Rodriguez-Perea AL, Rojas M, Velilla-Hernandez PA. High concentrations of atorvastatin reduce in-vitro function of conventional T and regulatory T cells. Clin Exp Immunol. 2019;196(2):237-248. https://doi.org/10.1111/cei.13260
70. Ajmera M, Shen C, Sambamoorthi U. Association between statin medications and COPD-specific outcomes: a real-world observational study. Drugs Real World Outcomes. 2017;4:9-19. https://doi.org/10.1007/s40801-016-0101-6
71. Kim WD. Phenotype of chronic obstructive pulmonary disease based on computed tomography-defined underlying pathology. Tuberc Respir Dis (Seoul). 2022;85(4):302-312. https://doi.org/10.4046/trd.2022.0029